Search

Artificial intelligence in medical devices: regulatory challenges and advances in Mexico and internationally | Health

Translated title. Original: Inteligencia artificial en dispositivos médicos: retos regulatorios y avances en México e internacional | Salud

AI in medical devices drives improved diagnostics and personalized treatment, but raises bias and data-quality concerns. Regulators in the US, EU, and Mexico are shaping frameworks to balance innovation with safety and reliability.

US health data: Final rule eliminates 14 of 60 certification criteria

Translated title. Original: US-Gesundheitsdaten: Schlussregel streicht 14 von 60 Zertifizierungskriterien

Regulators in Korea, China, the EU, and the US issue updates to digital medical devices, software updates, and AI rules, aiming to clarify approvals, streamline certifications, and emphasize interoperability and clinical evidence. The US and EU introduce significant changes, including reduced Health IT certification criteria, API-based interoperability, and mandates for meaningful clinical benefit in pharma-related software.

Medical devices in the EU: Experts call for a central agency with greater powers

Translated title. Original: Medizinprodukte in der EU: Fachleute fordern zentrale Agentur mit mehr Befugnissen

Experts advocate creating a centralized EU agency with binding powers to unify medical device regulation, citing fragmented MDR/IVDR oversight, slower market access, and declines in product launches; they point to historical centralization benefits and call for clearer timelines and support to industry.

Part II: How FDA predetermined change control plans create a market for AI medical device validation, clinical data procurement, software release controls, and recurring regulatory evidence services

The FDA allows pre-authorized updates for AI medical devices, but each update must have a full evidence package. Beacon Biosignals gained 510(k) clearance in 2024 under such plans, illustrating how predetermined change control creates a market for AI validation, data procurement, and ongoing regulatory evidence services.

AI Medical Device Post-Market Monitoring Market Size, 2033

The document analyzes regional trends in AI medical device post-market monitoring, highlighting North America’s leadership due to infrastructure and regulation, Asia-Pacific’s rapid growth driven by digital health expansion, and key markets like the U.S., Japan, Germany, and the UK with specific regulatory and market drivers. It notes regulatory actions, such as the U.S. FDA discussion on generative AI devices, and ongoing investments in data infrastructure and collaborations that propel market expansion.

MHRA brings AI device regulation plans to AdvaMed in US

MHRA uses AdvaMed 2026 to outline how it plans to regulate AI-enabled medical devices, including a new Washington-based liaison with the FDA. It highlights lifecycle-based regulation, sandboxes, and closer regulator cooperation, plus staffing moves and ongoing UK–US collaboration efforts.

Healthcare AI regulation must follow the product as it changes

EU and UK healthcare AI regulation diverge in approach; regulators emphasize the product’s ongoing lifecycle, with amended EU deadlines and a risk-based UK reform path that keeps existing medical-device obligations. For buyers and developers, clear separation of immediate requirements from future ones and precise product descriptions are essential to manage deployment and governance.

FDA Artificial Intelligence & AI/ML Device Rules — CASRAI

The document outlines FDA rules for AI/ML medical devices, including the four conditions for non-device clinical decision support and quality practices for model data, validation, and post-market monitoring. It notes that device classification depends on a software function’s purpose and capabilities.

Why software in medical technology is so tightly regulated | heise online

Translated title. Original: Warum Software in der Medizintechnik so streng reguliert ist | heise online

Software in medical technology is heavily regulated, with compliance based on intended use, risk class, and product complexity. Regulations, standards, and privacy laws shape the development lifecycle, documentation, and post-market updates.

Part I: How FDA predetermined change control plans create a market for AI medical device validation, clinical data procurement, software release controls, and recurring regulatory evidence services

FDA guidance allows pre-authorized AI device updates but requires a full evidence package for each release; governance of evidence across a full release program is key to managing drift and risk, illustrated by Beacon Biosignals' 510(k) clearance and the importance of study design and data dependencies.